Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will

In the now completed 30 mg zuranolone cohort, approximately 70% of participants with positive response to an initial 2-week treatment required at most one additional zuranolone treatment during the 12-month study After the initial 2-week zuranolone treatment, more than 70% of patients who received

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan , Sage’s Chief Operating

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year Progressed WATERFALL Study – now closed to enrollment – investigating zuranolone for as needed

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Catalyst rich 2021 includes expected topline readouts from ten clinical trials across the Company’s depression, neurology and neuropsychiatry franchises and in COVID-related ARDS Company committed to accelerating pipeline and expanding product engine with goal of delivering at least two

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

Barry Greene , a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders Jeff Jonas to assume new role of